AI Analysis
AI-generated analysis. Always verify with the original filing.
Fiscal 2025 was a challenging year for Connect Biopharma marked by sharp revenue declines and expanded losses as we accelerate development of lead candidate rademikibart.
Key Takeaways
1Revenue fell 99.8% year-over-year to $64.0K in FY2025, as 2024 included Simcere upfront and milestone payments.
2GAAP net loss widened 255.0% year-over-year to $55.5M in FY2025, driven by increased research and development costs for lead candidate rademikibart.
3GAAP operating loss expanded 158.7% year-over-year to $58.1M in FY2025, reflecting accelerated clinical investment in our lead pipeline candidate.
4Diluted GAAP EPS was -$1.00 in FY2025, compared to -$0.28 in FY2024, representing a 257.1% year-over-year decline.
5Net cash used in operating activities was $51.2M for FY2025, compared to $23.6M in FY2024, driven by a larger net loss and lower share-based compensation expense.